Joseph P. Hagan
2013 - Orexigen Therapeutics
In 2013, Joseph P. Hagan earned a total compensation of $1.9M as Former Chief Business and Financial Officer at Orexigen Therapeutics, a 53% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $214,600 |
|---|---|
| Option Awards | $1,328,412 |
| Salary | $370,000 |
| Other | $7,770 |
| Total | $1,920,782 |
Hagan received $1.3M in option awards, accounting for 69% of the total pay in 2013.
Hagan also received $214.6K in non-equity incentive plan, $370K in salary and $7.8K in other compensation.
Rankings
In 2013, Joseph P. Hagan's compensation ranked 4,031st out of 12,286 executives tracked by ExecPay. In other words, Hagan earned more than 67.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,031 out of 12,286 | 67th |
Division Manufacturing | 1,363 out of 4,612 | 70th |
Major group Chemicals And Allied Products | 369 out of 1,462 | 75th |
Industry group Drugs | 257 out of 1,156 | 78th |
Industry Pharmaceutical Preparations | 210 out of 890 | 76th |
Source: SEC filing on May 27, 2016.
Hagan's colleagues
We found four more compensation records of executives who worked with Joseph P. Hagan at Orexigen Therapeutics in 2013.
News
Regulus Therapeutics CEO Joseph Hagan's 2021 pay falls 22% to $1.8M
April 27, 2022
Regulus Therapeutics CEO Joseph Hagan's 2020 pay rises 16% to $2.3M
April 30, 2021
Regulus Therapeutics CEO Joseph Hagan's 2019 pay slips 14% to $2M
April 29, 2020
Regulus Therapeutics CEO Joseph Hagan's 2018 pay jumps 22% to $2.3M
July 1, 2019